Table 2.
Demographics and baseline characteristics of patients included in two comparative phase III community-acquired pneumonia studies of 2 g single-dose azithromycin microspheres (D’Ignazio et al 2005; Drehobl et al 2005)
|
Drehobl et al 2005 |
D’Ignazio et al 2005 |
|||
|---|---|---|---|---|
| Azithromycin microspheres (n = 247) | Clarithromycin XL 1.0 g (n = 252) | Azithromycin microspheres (n = 211) | Levofloxacin 500 mg (n = 212) | |
| Mean age (years) | 45.6 | 43.6 | 48.2 | 49.0 |
| No. of subjects ≥65 years (%) | 32 (13%) | 26 (10.3%) | 49 (23.2%) | 48 (22.6%) |
| Male/female | 112/135 | 134/118 | 121/90 | 109/103 |
| History of diabetes | 13 | 11 | 20 | 27 |
| Unilobar disease | 211 | 219 | 172 | 181 |
| Smoker/ex-smoker | 131 | 139 | 99 | 100 |
Abbreviation: XL, extended release.